Megestrol acetate

Generic Name: Megestrol acetate

Brand Names: Megace

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₂O_₄

CAS Number: 595-33-5

Unique Ingredient Identifier: TJ2M0FR8ES

Background: 17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.

Indication: For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.

Associated Conditions: Anorexia, Cachexia, Inoperable Carcinoma of Breast, Inoperable Endometrial Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Endometrial Carcinoma, Significant, Unexplained Weight Loss, Metastatic Endometrial carcinoma

Associated Therapies: Palliative Treatment

Clinical Trials

Megestrol Acetate Plus Rosuvastatin in Young Women with Early Endometrial Carcinoma

Phase 2

Active, not recruiting

Conditions: Endometrial Carcinoma Stage I

Interventions: Drug: Megestrol Acetate
Drug: Rosuvastatin

First Posted Date: 2020-07-29

Last Posted Date: 2025-03-12

Lead Sponsor: Fudan University

Target Recruit Count: 48

Registration Number: NCT04491643

Locations: 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China

iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children

Phase 4

Completed

Conditions: Feeding Behavior
Feeding Disorder of Infancy or Early Childhood

Interventions: Behavioral: iKanEat Behavioral Intervention
Drug: Megestrol Acetate

First Posted Date: 2019-01-24

Last Posted Date: 2025-05-07

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 71

Registration Number: NCT03815019

Locations: 🇺🇸
Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸
Arnold Palmer Hospital for Children, Orlando, Florida, United States
🇺🇸
Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States

and more 5 locations

Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

Phase 2

Active, not recruiting

Conditions: Atypical Endometrial Hyperplasia
Endometrial Carcinoma

Interventions: Drug: Megestrol Acetate
Biological: Pterostilbene

First Posted Date: 2018-09-14

Last Posted Date: 2025-03-26

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 44

Registration Number: NCT03671811

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Neoplasm Malignant Stage I

Interventions: Drug: Megestrol Acetate
Device: Levonorgestrel-releasing Intrauterine System(LNG-IUS)

First Posted Date: 2017-08-08

Last Posted Date: 2020-11-20

Lead Sponsor: Fudan University

Target Recruit Count: 64

Registration Number: NCT03241914

Locations: 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, Shanghai, China

Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia

Phase 2

Completed

Conditions: Atypical Endometrial Hyperplasia

Interventions: Device: Levonorgestrel-releasing Intrauterine System(LNG-IUS)
Drug: Megestrol Acetate

First Posted Date: 2017-08-08

Last Posted Date: 2020-06-18

Lead Sponsor: Fudan University

Target Recruit Count: 180

Registration Number: NCT03241888

Locations: 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, Shanghai, China

The Safety and Effect Study of Acupuncture for Anorexia in Patients With Gastrointestinal Tract and Lung Cancers

Phase 2

Conditions: Anorexia
Cancer Cachexia

Interventions: Other: Acupuncture
Other: Sham Acupuncture
Drug: Placebo(Megestrol Acetate)
Drug: Megestrol Acetate

First Posted Date: 2015-12-02

Last Posted Date: 2015-12-04

Lead Sponsor: Xinqiao Hospital of Chongqing

Target Recruit Count: 160

Registration Number: NCT02619266

Locations: 🇨🇳
Chongqing TCM Hospital, Jiangbei, Chongqing, China
🇨🇳
XinQiao Hosiptal, Shapingba, Chongqing, China
🇨🇳
Donghua Hosiptal, Shapingba, Chongqing, China

and more 1 locations

Phase II Study of Everolimus Beyond Progression

Phase 2

Terminated

Conditions: Estrogen Receptor-positive Breast Cancer
HER2-negative Breast Cancer
Progesterone Receptor-positive Breast Cancer
Stage IIIA Breast Cancer
Stage IV Breast Cancer
Recurrent Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer

Interventions: Drug: everolimus
Drug: anastrozole
Drug: letrozole
Drug: tamoxifen citrate
Drug: fulvestrant
Drug: megestrol acetate

First Posted Date: 2014-10-21

Last Posted Date: 2022-04-05

Lead Sponsor: Emory University

Target Recruit Count: 3

Registration Number: NCT02269670

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive
Asthma

Interventions: Drug: Berodual® Respimat®
Drug: Berodual® MA HFA

First Posted Date: 2014-06-25

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 245

Registration Number: NCT02173795

Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma

Phase 2

Completed

Conditions: Endometrial Adenocarcinoma
Endometrial Atypical Hyperplasia

Interventions: Drug: Megestrol acetate and metformin
Drug: Megestrol acetate

First Posted Date: 2013-10-24

Last Posted Date: 2021-09-14

Lead Sponsor: Xiaojun Chen

Target Recruit Count: 150

Registration Number: NCT01968317

Locations: 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳
Shanghai Changning Maternity & Infant Health Hospital, Shanghai, Shanghai, China
🇨🇳
Shanghai Sixth People's Hospital, Shanghai, Shanghai, China

and more 2 locations

Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer

Phase 2

Withdrawn

Conditions: Endometrial Adenocarcinoma
Stage IA Endometrial Carcinoma
Recurrent Endometrial Carcinoma
Stage IIIA Endometrial Carcinoma
Stage IIIC Endometrial Carcinoma
Stage IVA Endometrial Carcinoma
Stage IVB Endometrial Carcinoma
Atypical Endometrial Hyperplasia
Stage IB Endometrial Carcinoma
Stage II Endometrial Carcinoma

Interventions: Device: levonorgestrel-releasing intrauterine system
Drug: megestrol acetate
Other: laboratory biomarker analysis
Other: questionnaire administration

First Posted Date: 2013-09-16

Last Posted Date: 2014-09-10

Lead Sponsor: University of Southern California

Registration Number: NCT01943058

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy